Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 11 June 2024 AM
Johnson & Johnson's Invega franchise could be under threat in Australia with Teva Pharma registering the first generic of the schizophrenia treatment.
While J&J has numerous paliperidone-containing brands, Teva Pharma appears to be homing in on Invega Sustenna. Other J&J brands include oral Invega plus injectables Invega Trinza and Invega Hafyera.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.